The primary endpoint of the study is to identify a neurophysiological biomarker (absence of synaptic depotentiation at primary motor cortex , measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of neurophysiological cTBS depotentiation protocol) as predictor of the development of Levodopa-induced dyskinesia in patients with Parkinson's disease.

Inclusion Criteria:

• patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria;
• age between 30 and 80 years;
• ongoing therapy with levodopa;
• fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire.

Exclusion Criteria:

• patients unable to give informed consent;
• cognitive impairment (MMSE ≤ 24);
• history of epilepsy;
• pregnant women.